DAWN - NOTRELOAD AI

Featured/ DAWN/ 03/06/2026 · 8:56 AM

Servier to Buy Day One Biopharmaceuticals for $2.5 Billion to Lead in Childhood Brain Cancer

French pharma leader Servier acquires U.S. biotech Day One in a $2.5B cash deal to become #1 in pediatric low-grade glioma and expand rare cancer treatments for children and adults. Expected close: Q2 2026.

Featured/ DAWN/ 03/04/2026 · 1:40 PM

Day One Biopharmaceuticals Stock Jumps on Renewed M&A Rumors

Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.

MRSN/ 11/13/2025 · 8:37 AM

Day One Acquires Mersana for $285M to Gain Emi-Le Cancer Drug

Day One is acquiring Mersana Therapeutics for up to $285 million to gain Emi-Le, a promising new drug candidate for adenoid cystic carcinoma, a cancer with few treatment options.

#DAWN↓

Servier to Buy Day One Biopharmaceuticals for $2.5 Billion to Lead in Childhood Brain Cancer

Day One Biopharmaceuticals Stock Jumps on Renewed M&A Rumors

Day One Acquires Mersana for $285M to Gain Emi-Le Cancer Drug